Binding to Nonmethylated CpG DNA is Essential for Target Recognition, Transactivation, and Myeloid Transformation by an MLL Oncoprotein

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 2004 Nov 16

PMID 15542854

Citations 81

Authors

Paul M Ayton

Everett H Chen

Michael L Cleary

Affiliations

Soon will be listed here.

Abstract

The MLL gene is a frequent target for leukemia-associated chromosomal translocations that generate dominant-acting chimeric oncoproteins. These invariably contain the amino-terminal 1,400 residues of MLL fused with one of a variety of over 30 distinct nuclear or cytoplasmic partner proteins. Despite the consistent inclusion of the MLL amino-terminal region in leukemia oncoproteins, little is known regarding its molecular contributions to MLL-dependent oncogenesis. Using high-resolution mutagenesis, we identified three MLL domains that are essential for in vitro myeloid transformation via mechanisms that do not compromise subnuclear localization. These include the CXXC/Basic domain and two novel domains of unknown function. Point mutations in the CXXC domain that eliminate myeloid transformation by an MLL fusion protein also abolished recognition and binding of nonmethylated CpG DNA sites in vitro and transactivation in vivo. Our results define a critical role for the CXXC DNA binding domain in MLL-associated oncogenesis, most likely via epigenetic recognition of CpG DNA sites within the regulatory elements of target genes.

Citing Articles

Revumenib Revises the Treatment Landscape for -r Leukemia.

Heikamp E, Armstrong S J Clin Oncol. 2024; 43(1):85-88.

PMID: 39509656 PMC: 11771282. DOI: 10.1200/JCO-24-01265.

H3K4me2 distinguishes a distinct class of enhancers during the maternal-to-zygotic transition.

Hurton M, Miller J, Lee M bioRxiv. 2024; .

PMID: 39253505 PMC: 11383010. DOI: 10.1101/2024.08.26.609713.

Along the Bos taurus genome, uncover candidate imprinting control regions.

Wyss P, Song C, Bina M BMC Genomics. 2022; 23(1):478.

PMID: 35764919 PMC: 9241299. DOI: 10.1186/s12864-022-08694-3.

Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias.

Cantilena S, Gasparoli L, Pal D, Heidenreich O, Klusmann J, Martens J Clin Transl Med. 2022; 12(6):e933.

PMID: 35730653 PMC: 9214753. DOI: 10.1002/ctm2.933.

Missense variants causing Wiedemann-Steiner syndrome preferentially occur in the KMT2A-CXXC domain and are accurately classified using AlphaFold2.

Reynisdottir T, Anderson K, Boukas L, Bjornsson H PLoS Genet. 2022; 18(6):e1010278.

PMID: 35727845 PMC: 9249231. DOI: 10.1371/journal.pgen.1010278.

References

Emerling B, Bonifas J, Kratz C, Donovan S, Taylor B, Green E . MLL5, a homolog of Drosophila trithorax located within a segment of chromosome band 7q22 implicated in myeloid leukemia. Oncogene. 2002; 21(31):4849-54. DOI: 10.1038/sj.onc.1205615. View

Huth J, Bewley C, Nissen M, EVANS J, Reeves R, Gronenborn A . The solution structure of an HMG-I(Y)-DNA complex defines a new architectural minor groove binding motif. Nat Struct Biol. 1997; 4(8):657-65. DOI: 10.1038/nsb0897-657. View

Milne T, Briggs S, Brock H, Martin M, Gibbs D, Allis C . MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell. 2002; 10(5):1107-17. DOI: 10.1016/s1097-2765(02)00741-4. View

Nakamura T, Mori T, Tada S, Krajewski W, Rozovskaia T, Wassell R . ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell. 2002; 10(5):1119-28. DOI: 10.1016/s1097-2765(02)00740-2. View

So C, Cleary M . Common mechanism for oncogenic activation of MLL by forkhead family proteins. Blood. 2002; 101(2):633-9. DOI: 10.1182/blood-2002-06-1785. View

Strahl B, Ohba R, Cook R, Allis C . Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena. Proc Natl Acad Sci U S A. 1999; 96(26):14967-72. PMC: 24756. DOI: 10.1073/pnas.96.26.14967. View

Huntsman D, Chin S, Muleris M, Batley S, Collins V, Wiedemann L . MLL2, the second human homolog of the Drosophila trithorax gene, maps to 19q13.1 and is amplified in solid tumor cell lines. Oncogene. 2000; 18(56):7975-84. DOI: 10.1038/sj.onc.1203291. View

Fujita N, Shimotake N, Ohki I, Chiba T, Saya H, Shirakawa M . Mechanism of transcriptional regulation by methyl-CpG binding protein MBD1. Mol Cell Biol. 2000; 20(14):5107-18. PMC: 85960. DOI: 10.1128/MCB.20.14.5107-5118.2000. View

Lavau C, Du C, Thirman M . Chromatin-related properties of CBP fused to MLL generate a myelodysplastic-like syndrome that evolves into myeloid leukemia. EMBO J. 2000; 19(17):4655-64. PMC: 302066. DOI: 10.1093/emboj/19.17.4655. View

10.

DiMartino J, Miller T, Ayton P, Landewe T, Hess J, Cleary M . A carboxy-terminal domain of ELL is required and sufficient for immortalization of myeloid progenitors by MLL-ELL. Blood. 2000; 96(12):3887-93. View

11.

Rozovskaia T, Feinstein E, Mor O, Foa R, Blechman J, Nakamura T . Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality. Oncogene. 2001; 20(7):874-8. DOI: 10.1038/sj.onc.1204174. View

12.

Luo R, Lavau C, Du C, Simone F, Polak P, Kawamata S . The elongation domain of ELL is dispensable but its ELL-associated factor 1 interaction domain is essential for MLL-ELL-induced leukemogenesis. Mol Cell Biol. 2001; 21(16):5678-87. PMC: 87288. DOI: 10.1128/MCB.21.16.5678-5687.2001. View

13.

Ayton P, Sneddon S, Palmer D, Rosewell I, Owen M, Young B . Truncation of the Mll gene in exon 5 by gene targeting leads to early preimplantation lethality of homozygous embryos. Genesis. 2001; 30(4):201-12. DOI: 10.1002/gene.1066. View

14.

Ayton P, Cleary M . Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene. 2001; 20(40):5695-707. DOI: 10.1038/sj.onc.1204639. View

15.

Lee J, Voo K, Skalnik D . Identification and characterization of the DNA binding domain of CpG-binding protein. J Biol Chem. 2001; 276(48):44669-76. DOI: 10.1074/jbc.M107179200. View

16.

Armstrong S, Staunton J, Silverman L, Pieters R, den Boer M, Minden M . MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2001; 30(1):41-7. DOI: 10.1038/ng765. View

17.

Bird A . DNA methylation patterns and epigenetic memory. Genes Dev. 2002; 16(1):6-21. DOI: 10.1101/gad.947102. View

18.

Pineault N, Helgason C, Lawrence H, Humphries R . Differential expression of Hox, Meis1, and Pbx1 genes in primitive cells throughout murine hematopoietic ontogeny. Exp Hematol. 2002; 30(1):49-57. DOI: 10.1016/s0301-472x(01)00757-3. View

19.

Birke M, Schreiner S, Garcia-Cuellar M, Mahr K, Titgemeyer F, Slany R . The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation. Nucleic Acids Res. 2002; 30(4):958-65. PMC: 100340. DOI: 10.1093/nar/30.4.958. View

20.

Ruault M, Brun M, Ventura M, Roizes G, De Sario A . MLL3, a new human member of the TRX/MLL gene family, maps to 7q36, a chromosome region frequently deleted in myeloid leukaemia. Gene. 2002; 284(1-2):73-81. DOI: 10.1016/s0378-1119(02)00392-x. View